Production (Stage)
Protalix BioTherapeutics, Inc.
PLX
$1.58
$0.063.95%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 169.82% | 73.74% | 73.60% | -61.59% | -60.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 169.82% | 73.74% | 73.60% | -61.59% | -60.91% |
| Cost of Revenue | 214.37% | -56.12% | 71.16% | 53.81% | -15.66% |
| Gross Profit | 68.67% | 779.26% | 75.79% | -86.11% | -82.38% |
| SG&A Expenses | -16.44% | -27.61% | -29.29% | -13.57% | 0.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.71% | -31.63% | 14.19% | 8.51% | -28.58% |
| Operating Income | 14.64% | 228.39% | 311.50% | -111.88% | -97.48% |
| Income Before Tax | 21.15% | 213.85% | 323.56% | -111.56% | -61.21% |
| Income Tax Expenses | 18.12% | 315.18% | 356.39% | -122.40% | -170.77% |
| Earnings from Continuing Operations | 21.24% | 207.45% | 274.73% | -111.39% | -46.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.24% | 207.45% | 274.73% | -111.39% | -46.76% |
| EBIT | 14.64% | 228.39% | 311.50% | -111.88% | -97.48% |
| EBITDA | 16.21% | 242.27% | 373.07% | -110.18% | -108.08% |
| EPS Basic | 24.96% | 211.18% | 271.88% | -110.45% | -15.41% |
| Normalized Basic EPS | 24.94% | 217.72% | 319.46% | -110.61% | -26.96% |
| EPS Diluted | 24.96% | 176.44% | 178.01% | -114.33% | -15.41% |
| Normalized Diluted EPS | 24.94% | 179.20% | 331.25% | -113.14% | -26.96% |
| Average Basic Shares Outstanding | 4.90% | -3.30% | 1.75% | 9.16% | 27.06% |
| Average Diluted Shares Outstanding | 4.90% | 43.67% | -3.06% | -11.89% | 27.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |